Preventing GVHD: T-Cell Depletion versus Post-Transplant Cyclophosphamide
Thursday, May 30, 2024 05:00 PM - 06:00 PM
Room 208-209
Roundtable
Organized by: ISCT Stem Cell Engineering Committee
Moderator(s)
Key Learning Objectives
1. Where are we at with GVHD prophylaxis - is PTCy as good as it gets?
2. What advantages do ex vivo T-cell depletion strategies offer, and can they be further optimised?
3. What are the barriers to widespread roll-out of ex-vivo T-cell depletion for GVHD prophylaxis
Moderator(s)
- Duncan Purthill, MBBS FRACP FRCPA, Fiona Stanley Hospital, Australia
- Alice Bertaina, MD, PhD, Stanford School of Medicine, United States
- Orly Klein, MD, PhD, Stanford Schoool of Medicine, United States
- Portia Smallbone, MBBS ( Stem cell transplant and cellular therapy fellow) MD Anderson Cancer Center
- Madhavi Lakkaraja, Assistant Professor, Fred Hutch Cancer Research Center
Key Learning Objectives
1. Where are we at with GVHD prophylaxis - is PTCy as good as it gets?
2. What advantages do ex vivo T-cell depletion strategies offer, and can they be further optimised?
3. What are the barriers to widespread roll-out of ex-vivo T-cell depletion for GVHD prophylaxis
Portia Smallbone
Stem Cell Transplant and Cellular Therapy Fellow
MD Anderson Cancer Center
Panelist
Stem Cell Transplant and Cellular Therapy Fellow
MD Anderson Cancer Center
Panelist